Syndax Pharmaceuticals Inc (SNDX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Syndax Pharmaceuticals Inc's filing signal turned positive.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies. The company has two FDA-approved medicines: Revuforj (revumenib), a menin inhibitor for acute leukemia with KMT2A translocations and NPM1 mutations, and Niktimvo (axatilimab-csfr), a CSF-1R blocking antibody for chronic graft-versus-host disease. Syndax is advancing clinical development programs for both products, exploring new indications and combinations, including for myelofibrosis and idiopathic pulmonary fibrosis. The company's strategy involves successfully commercializing its approved products in the U.S., expanding its pipeline through licensing and acquisition, and leveraging its management team's expertise. Syndax operates in the biopharmaceutical industry, with a primary focus on oncology.

Revenue is driven by net product sales of Revuforj and Niktimvo, as well as collaboration revenue, milestone payments, and royalties from license agreements.